Literature DB >> 22738680

Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis.

Yves Allenbach1, Olivier Benveniste, Valérie Decostre, Aurélie Canal, Bruno Eymard, Serge Herson, Coralie Bloch-Queyrat, Jean-Yves Hogrel.   

Abstract

There are currently no effective treatments to restore the muscle function in sporadic inclusion body myositis. Natural history studies of this disease are scarce. The goal of this study consisted in defining the functional pattern of patients with sporadic inclusion body myositis and to follow its change over a 9-month period to determine the most sensitive outcome measures for future clinical trials. Twenty-two patients with definite sporadic inclusion body myositis were assessed using clinical and functional scales. Dynamometry was used to evaluate the strength for hand grip and wrist, elbow, ankle and knee flexion and extension. Among the patients, 16 were reassessed 9months later. The mean whole composite index was at 43.3±16.5% of the predicted normal values. The weakest muscle functions were hand grip, wrist flexion and elbow flexion at the upper limbs and knee extension and ankle flexion at the lower limbs. Muscle weakness was generally asymmetrical, especially for upper limbs where all tested functions were significantly stronger at the dominant side. The patient strength was correlated with the disease duration only for knee extension, which was also the only muscle function to change significantly over 9months. Knee extension strength seems to be the most relevant marker of disease progression in sporadic inclusion body myositis when measured with suitable dynamometry.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22738680     DOI: 10.1016/j.nmd.2012.05.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  14 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 2.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

3.  Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study.

Authors:  Giorgia Querin; Timothée Lenglet; Rabab Debs; Tanya Stojkovic; Anthony Behin; François Salachas; Nadine Le Forestier; Maria Del Mar Amador; Gaëlle Bruneteau; Pascal Laforêt; Sophie Blancho; Véronique Marchand-Pauvert; Peter Bede; Jean-Yves Hogrel; Pierre-François Pradat
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

4.  Safety and feasibility of maximal physical testing in rheumatic diseases: a cross-sectional study with 5,910 assessments.

Authors:  Rodrigo Branco Ferraz; Bruno Gualano; Carlos Merege Filho; Murilo Groschitz Almeida; Luiz Augusto Perandini; Thalita Dassouki; Ana Lúcia Sá-Pinto; Fernanda Rodrigues Lima; Hamilton Roschel
Journal:  Rheumatol Int       Date:  2014-11-06       Impact factor: 2.631

5.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

6.  Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

Authors:  Kubéraka Mariampillai; Benjamin Granger; Damien Amelin; Marguerite Guiguet; Eric Hachulla; François Maurier; Alain Meyer; Aline Tohmé; Jean-Luc Charuel; Lucile Musset; Yves Allenbach; Olivier Benveniste
Journal:  JAMA Neurol       Date:  2018-12-01       Impact factor: 18.302

7.  Ankle dorsi- and plantar-flexion torques measured by dynamometry in healthy subjects from 5 to 80 years.

Authors:  Amélie Moraux; Aurélie Canal; Gwenn Ollivier; Isabelle Ledoux; Valérie Doppler; Christine Payan; Jean-Yves Hogrel
Journal:  BMC Musculoskelet Disord       Date:  2013-03-22       Impact factor: 2.362

Review 8.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423

9.  CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy.

Authors:  Fernanda Pinto-Mariz; Luciana Rodrigues Carvalho; Alexandra Prufer De Queiroz Campos Araujo; Wallace De Mello; Márcia Gonçalves Ribeiro; Maria Do Carmo Soares Alves Cunha; Pedro Hernan Cabello; Ingo Riederer; Elisa Negroni; Isabelle Desguerre; Mariana Veras; Erica Yada; Yves Allenbach; Olivier Benveniste; Thomas Voit; Vincent Mouly; Suse Dayse Silva-Barbosa; Gillian Butler-Browne; Wilson Savino
Journal:  Skelet Muscle       Date:  2015-12-10       Impact factor: 4.912

Review 10.  Update in inclusion body myositis.

Authors:  Pedro Machado; Stefen Brady; Michael G Hanna
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.